Navigation Links
MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/1/2011

Announced results from a clinical trial comparing the pharmacokinetics and safety of LEVADEX and intravenous dihydroergotamine (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.
  • Announced results from a pharmacodynamics trial evaluating pulmonary artery pressure in healthy volunteers using echocardiogram. The trial compared acute effects on pulmonary artery pressure of LEVADEX, DHE administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.
  • Announced results from a thorough QT trial in healthy adults comparing the acute effects of a supra-therapeutic dose of LEVADEX, oral moxifloxacin and placebo on the cardiac QT interval as measured by electrocardiogram. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals.  
  • Announced completion of the LEVADEX open-label safety trial. In total, more than 475 patients completed six months treatment and more than 250 patients completed 12 months treatment.  No drug-related serious adverse events were reported.
  • Presented additional analyses of the LEVADEX Phase 3 FREEDOM-301 trial at various medical meetings, including data for LEVADEX in a broad spectrum of acute migraine attacks; menstrual migraine; allodynic patients; resistant migraine; patients with concomitant asthma; migraine recurrence; and the administration of LEVADEX at different time points during migraine attacks.

  • Corporate

  • Announced a collaboration with Allergan to co-promote LEVADEX to neurologists and pain specialists in the United States for th
    '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
    4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
    5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
    6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
    7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
    8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
    9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
    10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
    11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/30/2015)... 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced ... Resverlogix have approved the resolutions relating to: (i) ... 5,600,000 units at a price of $2.67 per ... comprised of one common share and 0.075358 common ... CAD$15 million; and (ii) the amendment to Resverlogix,s ...
    (Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner ... mechanics of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome ... undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. ...
    (Date:6/30/2015)... , June 30, 2015  The University of ... Biosciences (CCE/Bio) and UC San Diego Extension announced ... be held Aug.  12 – 14, 2015, at ... three-day workshop provides an intense exposure to best ... and is well-suited to biologists, process engineers and ...
    (Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... prior to launching SmartArch — a revolutionary new archwire that allows orthodontists to ... further clinical evidence of the efficacy of SmartArch. “We’re thrilled about taking SmartArch ...
    Breaking Biology Technology:Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2
    ... , , BOTHELL, Wash., Aug. 7 ... reported financial results for the three and six months ended June ... Morra, SCOLR Pharma,s President and CEO, said, "We continue to advance ... release ibuprofen. These potential partners have been committing resources to due ...
    ... EXTON, Pa., Aug. 7 Kensey Nash Corporation ... the distribution rights, along with the trademark, inventory and ... product line. Under the terms of the agreement, the ... existing OsseoFit distribution agreement. Pursuant to the agreement, following ...
    ... , CORAL GABLES, Fla., Aug. 7 Catalyst Pharmaceutical Partners, Inc. ... and six months ended June 30, 2009. , , ... For the quarter ended June 30, 2009, the Company reported a net loss ... loss of $2,377,440, or $0.19 per basic and diluted share for the same ...
    Cached Biology Technology:SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results 8Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 7
    (Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
    (Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
    (Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
    Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
    ... a major food source for much of the world, rice is ... safe from disease has become, in part, the task of a ... Kansas State University. The researchers are looking at two bacterial ... which is caused by a bacterium called Xanthomonas oryzae pathovar ...
    ... Engineers at Oregon State University have made a major ... run a cooling system a technology that can improve ... will appear in automobiles, homes and industry. This heat-actuated ... the U.S. Army, could ultimately be applied to automobiles, factories ...
    ... herders are facing the challenges of adapting to climate ... for herds to find food and navigate. To help ... them with satellite-based snow maps. "Snow is of ... whether reindeer are able to access the pastures that ...
    Cached Biology News:Researchers examine bacterial rice diseases, search for genetic solutions 2Breakthrough made in energy efficiency, use of waste heat 2Breakthrough made in energy efficiency, use of waste heat 3Satellite snow maps help reindeer herders adapt to a changing Arctic 2
    Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
    BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
    Mycoplasma and virus tested...
    Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
    Biology Products: